Xeris Biopharma Holdings Inc (XERS) USD0.0001

- Add to watchlist
- This stock can be held in a




Business summary
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
Contact details
Important dates
General stock information
- Short code:
- XERS
- ISIN:
- US98422E1038
- Market cap:
- $220.92 million
- Shares in issue:
- 135.53 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.